- Open Access
Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study
Clinical and Translational Allergyvolume 9, Article number: 33 (2019)
Platelet activating factor (PAF) is an endogenous, active phospholipid released from inflammatory cells, platelets, and endothelial cells, and is involved in the regulation of immune responses. Degradation of PAF by PAF acetylhydrolase (PAF-AH) has been shown to be associated with anaphylaxis, asthma, and peanut allergy. The purpose of this study was to investigate relationships among clinical parameters, including urticaria severity and treatment responsiveness, and PAF and PAF-AH levels in sera from patients with chronic spontaneous urticaria (CSU).
Serum PAF and PAF-AH levels were measured by enzyme-linked immunosorbent assay in 283 CSU patients and 111 age- and sex-matched, healthy normal controls (NCs). Urticaria severity was evaluated by urticaria activity score over 7 days (UAS7). Within 3 months after measuring PAF levels, patients whose urticaria was not controlled by antihistamine treatment were classified as histamine receptor 1 antagonist (H1RA) non-responders.
Serum PAF levels were significantly higher in CSU patients than in NCs (median 4368.9 vs. 3256.4 pg/ml, p = 0.015), while serum PAF-AH levels were significantly lower in CSU patients (105.6 vs. 125.7 ng/ml, p = 0.001). H1RA non-responders had higher levels of PAF in their sera than H1RA responders. A generalized linear model revealed that a higher UAS7 score (odds ratio 1.023, p = 0.024) and a PAF level ≥ 5000 pg/ml (1.409, p < 0.001) were significant predictors of a poor response to H1RA treatment.
Compared with NCs, CSU patients, particularly those with H1RA refractoriness, showed significant increases in serum PAF levels and decreases in PAF-AH. Therapies modulating PAF and PAF-AH levels could be effective in patients with CSU refractory to antihistamines.
Platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a bioactive phospholipid that plays a critical role in immune and inflammatory conditions . It has been found to be produced by most immune cells, including basophils, eosinophils, mast cells, lymphocytes, and macrophages, as well as platelets and endothelial cells . PAF binds to its specific receptor PAFR, a G protein-coupled receptor expressed on several immune cells, including mast cells and basophils . Metabolism of PAF is regulated by the enzyme PAF-acetylhydrolase (PAF-AH), which is responsible for PAF degradation. PAF has been found to be involved in the pathogenesis of cardiovascular diseases, psoriasis, sepsis, and allergic diseases, including asthma, allergic rhinitis, anaphylaxis, and urticaria [1, 3,4,5].
Chronic urticaria (CU) is a chronic inflammatory skin disorder characterized by recurrent itchy wheals lasting longer than 6 weeks. CU is classified into inducible urticaria (induced by specific physical triggers) and chronic spontaneous urticaria (CSU) . Resulting in vasodilatation, plasma extravasation, and inflammatory cell migration to urticarial lesions, mast cells and basophils release various inflammatory mediators, including histamine, protease, cytokines, chemotactic factors, arachidonic acid metabolites, neuropeptides, and PAF . Accordingly, recent guidelines recommend non-sedating H1 antihistamines (histamine1 receptor antagonist, H1RA) for first-line treatment of CSU . Except for histamine, however, the roles of inflammatory mediators in the pathogenesis of CSU have yet to be thoroughly investigated.
Research suggests that PAF plays an important role in anaphylactic reactions, being correlated with the severity thereof [1, 7]. Interestingly, in severe anaphylaxis, PAF levels have been found to be inversely correlated with PAF-AH levels . The present study aimed to investigate associations of PAF and PAF-AH levels in sera in relation to clinical implications in CSU patients.
In total, 283 patients with CSU who had urticaria symptoms for more than 6 weeks and 111 healthy normal controls (NCs) were recruited. Inclusion criteria were age ≥ 19 years and having urticaria symptoms almost daily, such as wheals and itching or angioedema, for at least 6 weeks. Patients with other chronic skin diseases and those with clinical evidence of urticarial vasculitis or inducible (physical stimuli or cholinergic or exercise) urticaria were excluded. Sera from healthy normal controls were supplied by the Ajou University Human Bio-Resource Bank. Normal controls (NCs) were confirmed by the Biobank as not having any previous history of inflammatory or allergic skin disease or urticaria.
UAS7 (urticarial activity score over 7 days), a weekly urticaria activity score, was utilized to assess disease activity . Body mass index (BMI) was calculated as weight/height (kg/m2). Aspirin intolerance was diagnosed based on a history of recurrent urticaria after aspirin/non-steroidal anti-inflammatory drug (NSAID) ingestion or positive results of oral challenge to aspirin, as previously described . Written informed consent was collected from all study subjects. The study was approved by the Institutional Review Board of Ajou University Medical Center (AJIRB-BMR-SMP-18-74).
Assessment of clinical parameters
Autologous serum skin test (ASST) was performed and evaluated in accordance with reported guidelines . Atopy was defined as at least one positive skin test result to common allergens or increased serum levels of specific Immunoglobulin E (IgE) to Dermatophagoides farina, D.pteronyssinus, or other common inhalant allergens. Anti-nuclear antibody (ANA) was detected using an indirect fluorescent antibody technique (Fluoro HEPANA test, Medical & Biological Laboratories, Nagoya, Japan). Total IgE and eosinophilic cationic protein (ECP) were measured by the ImmunoCAP system (Pharmacia Diagnostics, Uppsala, Sweden) according to the manufacturer’s instruction. Total cholestrol, triglyceride, and high and low density lipoproteins (HDL and LDL) were measured by enzymatic colorimetric assay using a TBA-200FR anlalyser (Toshiba, Tokyo, Japan). Complement 3 and 4 levels were measured using an immunoturbidimetric assay (Roche Hitachi Cobas C system, Rotkreuz, Switzerland). Antihistamine doses were described as equivalent doses of loratadine (mg/day).
Serum PAF and PAF-AH levels
Before collecting serum samples, antihistamines were withdrawn for at least 5 days. Serum samples were stored at − 70 °C until ready for use. Serum PAF and PAF-AH levels were measured by commercial enzyme-linked immunoabsorbent assay (ELISA) kits (LifeSpan BioSciences, Inc., Seattle, WA, USA and R&D systems Inc., Minneapolis, MN, USA, respectively). The serum samples were diluted based on the detection ranges of PAF (78.3–5000 pg/ml) and PAF-AH (0.781–50 ng/ml).
Statistical analyses were performed using IBM SPSS, version 25 for Windows (SPSS Inc., Chicago, IL, USA). Data are presented as a mean ± standard deviation for clinical parameters and as a median (interquartile range [IQR]) for PAF and PAF-AH. As distributions of total IgE levels in both CSU and NC groups, were highly right-skewed, total IgE were logarithmically transformed (base 10) for statistical analyses. Statistical significance was assessed by Mann–Whitney U-test or Fisher’s exact test, and correlation analyses were conducted by Spearman’s correlation. The level of PAF ≥ 5000 pg/mL was obtained as the cut-off for detecting non-responders to antihistamines based on receiver operator characteristics (ROC) curve analysis (area under the curve 0.642, p < 0.001). A generalized linear model was applied to determine the effects of PAF and PAF-AH on treatment response in CSU patients.
Characteristics of study subjects
The clinical characteristics of study subjects are summarized in Table 1. We enrolled 283 CSU patients (42.4 ± 11.7 years old, 184 females) and 111 age- and sex-matched NCs (43.9 ± 11.3 years old, 73 females). BMI was not different between the CSU patients and NCs (23.5 ± 3.9 vs. 23.1 ± 2.8 kg/m2, p = 0.864). The mean urticaria duration was 26.1 months, and the mean UAS7 score was 24.4 ± 10.3. The prevalences of angioedema and aspirin intolerance were 45.7% and 25.5% in CSU patients, respectively. Among the CSU patients, 30.2% had a positive response to ASST, and 21.4% were positive on ANA. The atopy rate was 54.2%, and the mean level of log-transformed total IgE (kU/L) was 2.09 ± 0.5 in CSU patients. Mean serum ECP level was higher in CSU patients than in NCs (21.7 ± 18.9 vs. 12.7 ± 9.6 kU/L, p < 0.001). Compared with NCs, patients with CSU had higher levels of log-transformed total IgE (p < 0.001) and triglycerides (150.4 ± 98.7 vs. 104.2 ± 60.0 mg/dL, p < 0.001) and lower levels of HDL (55.7 ± 14.9 vs. 70.2 ± 27.0 mg/dL, p < 0.001), whereas no significant differences in total cholesterol and LDL were observed.
H1RA non-responders were defined as patients whose symptoms could not be controlled by increasing doses of antihistamines (up to fourfold) within 3 months, and H1RA responders were defined as those who responded well to antihistamine treatment . The clinical characteristics of patients according to H1RA response are summarized in Table 2. There were no differences in age (42.3 ± 12.0 vs. 42.6 ± 11.4 years, p = 0.665) or sex (female 65.7 vs. 64.6%, p = 0.852) between H1RA responders and non-responders, nor were there any significant differences in BMI (23.4 ± 4.1 vs. 23.6 ± 3.6, p = 0.577). The mean urticaria duration of the H1RA responder group was 28.8 ± 56.8 months, and that for the H1RA non-responder group was 22.1 ± 43.0 months (p = 0.289). No differences were observed in serum total IgE and complement levels or lipid profiles between the two groups.
H1RA non-responders had higher UAS7 scores than those who responded well to H1RA treatment (28.8 ± 9.3 vs. 24.4 ± 10.3, p < 0.001) at initial visits. They also had higher H1RA requirements calculated as the equivalent dose of loratadine (mg/day) (21.0 ± 9.4 vs. 30.8 ± 13.3, p < 0.001) for a subsequent 3 months after enrollment into the present study.
Serum PAF and PAF-AH levels in CSU patients and NCs
The median level of serum PAF was remarkably higher in CSU patients than in NCs (4368.9 [17.0–14768.3] vs. 3256.4 [27.1–13886.7] pg/ml, p = 0.015, Fig. 1a), while the median PAF-AH level was comparably lower in CSU patients than in NCs (105.6 [2.6–296.4] vs. 125.7 [2.0–291.1] ng/ml, p < 0.001, Fig. 1b). When we analyzed the ratio of PAF-AH to PAF, CSU patients had significantly lower PAF-AH/PAF ratios than NCs (Fig. 1c). However, there was no correlation between serum PAF and PAF-AH levels (r = 0.081, p = 0.175) in either CSU patients or NCs.
Associations for serum PAF and PAF-AH levels with treatment response
Interestingly, the median level of serum PAF was higher in H1RA non-responders than in H1RA responders (5426.3 [53.1–14768.3] vs. 3804.5 [17.0–11716.3] pg/mL, p < 0.001, Fig. 2a), while PAF-AH levels were not (104.2 [2.6–296.4] vs. 112.0 [4.4–256.8] ng/mL, p = 0.051, Fig. 2b). PAF-AH/PAF ratio was also higher in H1RA responders than in H1RA non-responders (124.5 ± 569.0 vs. 70.8 ± 278.8 ng/mL, p = 0.007, Fig. 2c).
With a cut-off level for PAF of 5000 pg/mL obtained by ROC curve analysis, we divided CSU subjects and NCs with PAF levels ≥ 5000 pg/mL, particularly between H1RA responder and non-responders. Among CSU patients, 117 (41.3%) had PAF levels at least 5000 pg/mL in their sera, whereas the rate of high PAF (≥ 5000 pg/mL) in NCs was 29.7% (p = 0.038, Fig. 3). The rate of patients with high PAF was more frequent among H1RA non-responders than among H1RA responders (57.5 vs. 30.2%, p < 0.001, Fig. 3).
To identify predictors of responsiveness to antihistamine treatment in patients with CSU, we performed multivariate analysis using a generalized linear model containing age, sex, urticaria duration, UAS7, total IgE levels, BMI, ASST response, PAF-AH levels, and PAF ≥ 5000 pg/mL as covariates. Higher UAS7 scores (odds ratio 1.008, 95% confidence interval 1.001–1.016, p = 0.020) and PAF ≥ 5000 pg/mL (1.414, 1.217–1.642, p < 0.001) were found to be significant factors for discriminating H1RA non-responders among CSU patients (Table 3).
With regard to serum PAF in CSU patients, no correlations with clinical parameters were observed (r = 0.042, p = 0.523 for BMI; r = 0.067, p = 0.264 for urticaria duration; r = 0.103, p = 0.084 for UAS7). Serum PAF-AH levels, however, were correlated positively with BMI (r = 0.131, p = 0.04) and negatively with urticaria duration (r = − 0.121, p = 0.045), while no correlation was found with UAS7 (r = 0.07, p = 0.215). PAF-AH showed positive correlations with C3 (r = 0.163, p = 0.007) and C4 (r = 0.185, p = 0.002) levels and total cholesterol (r = 0.231, p < 0.001) and triglyceride (r = 0.192, p = 0.014) levels in the sera of patients with CSU, whereas PAF did not (r = − 0.067, p = 0.275 for C3; r = − 0.031, p = 0.613 for C4; r = 0.029, p = 0.264 for total cholesterol; r = 0.133, p = 0.089 for triglyceride). No correlations were found between total IgE and ECP levels with either PAF (r = 0.032, p = 0.600 for total IgE; r = 0.123, p = 0.092 for ECP) or PAF-AH (r = − 0.023, p = 0.699 for total IgE; r = − 0.05, p = 0.451 for ECP) levels in the sera of CSU patients. Mean medication score (daily H1RA requirement defined as mean loratadine dose) was positively correlated with serum PAF-AH levels (r = 0.153, p = 0.019), but not with PAF levels (r = − 0.014, p = 0.835).
The present study demonstrates that PAF levels are increased and that PAF-AH levels are decreased in the sera from CSU patients, compared with those in healthy controls. These results are consistent with previous reports on increased PAF levels in anaphylactic patients [8, 12] and in asthmatics .
PAF is a rapid synthesizing, potent signaling phospholipid produced in response to stress, chemotactic factors, phagocyte stimulation, exogenous antigens or IgE/IgG, thrombin, IL-1, bacteria, or calcium ionophore . PAF is synthesized and released from various immune cells, including neutrophils, monocytes, macrophages, platelets, eosinophils, and vascular endothelial cells , and accumulating evidence indicates that PAF is involved in inflammation and coagulation through its specific receptor expressed on a wide variety of cell surfaces . PAF induces aggregation and activation of neutrophils to produce reactive oxygen species and eicosanoids, and PAF can augment IL-1, IL-6, and tumor necrosis factor (TNF) production via human cells. Meanwhile, IL-1 and TNF promotes the release of PAF in neutrophils, macrophages, and endothelial cells. Prior reports of perivascular cellular infiltration of neutrophils, eosinophils, T cells, and monocytes, as well as increased expression of IL-6 and TNF-α, in urticarial lesions  suggest that PAF could be a key player in the pathogenesis of CU. Indeed, intradermal injection of PAF has been found to induce transient wheals with increases in vascular permeability followed by neutrophil infiltration .
Previously, Amin et al.  reported that neutrophilic infiltrates on skin biopsy from CU patients is a marker of poor control. In the present study, a high level of serum PAF (> 5000 pg/mL) in CSU patients was identified as a novel predictor of a poor response to antihistamine treatment: higher PAF levels can lead to massive neutrophil chemotaxis and finally result in H1RA resistance. PAF has a short half-life (3–13 min) due to its fast metabolism by circulating PAF-AH, which also degrades oxidized phospholipids . We found increased PAF levels and a lower PAF-AH to PAF ratio in CSU patients, compared with NCs. This suggests that impaired degradation of PAF caused by decreased PAF-AH levels might be a reason for increased PAF levels in CSU patients. However, we only found a marginal and statistically insignificant difference in PAF-AH levels between CSU patients and NCs and no difference according to H1RA treatment responses among CSU patients. The secretion of PAF-AH is regulated by various cytokines, as well as steroid hormones and gender. Pro-inflammatory cytokines known to be elevated in CSU patients, including IL-6, TNF-α, and interferon-gamma (IFN-γ), can stimulate macrophages to express both PAF-AH and complement as a physiologic response . Accordingly, we noted significant correlations between PAF-AH and complements 3 and 4 in CSU patients in the present study. Moreover, we previously reported the co-existence of metabolic syndrome in severe refractory urticaria patients who had higher complement levels . Additionally, increased levels of PAF-AH and LDL were found to be associated with abdominal adiposity in obese children and adults with metabolic syndrome [20, 21]. Interestingly, in the present study, significant correlations for BMI, total cholesterol, triglyceride, and complement levels with serum PAF-AH levels in patients with CSU were also observed. Consistent with previous reports in which estrogen was found to decrease PAF-AH levels, we also found that females had significantly lower levels of PAF-AH than males among both CSU patients and NCs . However, because no difference was observed in PAF-AH levels between H1RA responders and non-responders, the pathologic effects of PAF-AH in CSU remains to be elucidated.
Research has demonstrated that recombinant PAF-AH attenuates inflammation in a variety of experimental models and that genetic deficiency of PAF-AH increases the severity of atherosclerosis and other inflammatory syndromes . Correlating with severity, PAF-AH has been found to be decreased in both asthmatic patients and mice [22, 23]. Moreover, reports have indicated that human PAF is associated with increased nasal airway resistance to histamine and nasal symptoms [24, 25]. A PAFR deficient asthma mouse model showed reduced airway hyper-responsiveness [22, 26, 27], and studies have revealed correlations between increased PAF levels and anaphylaxis severity [8, 12]. Accordingly, inactivation of PAF or PAF receptor antagonist has been proven to prevent anaphylaxis in vivo [28, 29].
The estimated prevalence of CSU worldwide is around 0.5–1%, and 50% of CSU individuals do not achieve control with H1RA treatment . While biomarkers to predict H1RA responsiveness in CSU patients would be helpful, evidence thereof is sparse. Meanwhile, an increase in serum levels of lipocalin-2 has been suggested as a useful biomarker with which to determine clinical responses to antihistamine treatment in CSU patients: this biomarker has also been shown to be correlated with metabolic syndrome and obesity [11, 31]. Additionally, D-dimer, fibrinogen, C-reactive protein, and erythrocyte sedimentation rate have been highlighted as promising biomarkers for predicting poor responses to antihistamine treatment . Also, increases in IL-6 have been reported in refractory CU . Notably, these features of activating coagulation and chronic low-grade inflammation, which are observed in severe CU, can be linked with increases in PAF levels and PAF-induced coagulation and inflammation.
Rupatadine is a long-acting H1-antihistamine that antagonizes PAF and has recently been shown to be effective in allergic diseases, including urticaria [34, 35]. It has been found to decrease the severity of peanut-induced anaphylaxis and to alleviate symptoms of allergic rhinoconjunctivitis and cold urticaria [36,37,38]. As indicated in multivariate analysis in the present study, higher UAS7 score and high PAF levels (PAF ≥ 5000 pg/mL) at baseline could be significant predictors of a poor response to H1RA treatment. Therapeutic strategies to inhibit PAF or to stimulate PAF-AH might be beneficial for H1RA refractory CSU patients.
In conclusion, we found serum levels of PAF to be increased and PAF-AH levels to be decreased in CSU patients, compared with healthy controls. Accordingly, we propose that high levels of PAF in serum could be a potential predictor of refractoriness to antihistamine treatment in CSU patients. For severe patients with high UAS7 scores, increasing antihistamines with the addition of a PAF antagonist may help to achieve better control of CU earlier. Further studies are required to elucidate PAF and PAF-AH signaling and therapeutic modulation thereof in CSU.
Availability of data and materials
autologous serum skin test
body mass index
chronic spontaneous urticaria
eosinophil cationic protein
enzyme-linked immunosorbent assay
histamine receptor 1 antagonist
high density lipoprotein
low density lipoprotein
healthy normal control
platelet activating factor
platelet activating factor acetylhydrolase
receiver operating characteristic
tumor necrosis factor
urticaria activity score
urticaria activity score over 7 days
Gill P, Jindal NL, Jagdis A, Vadas P. Platelets in the immune response: revisiting platelet-activating factor in anaphylaxis. J Allergy Clin Immunol. 2015;135:1424–32.
Honda Z, Ishii S, Shimizu T. Platelet-activating factor receptor. J Biochem. 2002;131:773–9.
Izaki S, Yamamoto T, Goto Y, Ishimaru S, Yudate F, Kitamura K, et al. Platelet-activating factor and arachidonic acid metabolites in psoriatic inflammation. Br J Dermatol. 1996;134:1060–4.
Tjoelker LW, Stafforini DM. Platelet-activating factor acetylhydrolases in health and disease. Biochim Biophys Acta. 2000;1488:102–23.
Chandrashekar L, Rajappa M, Sundar I, Munisamy M, Ananthanarayanan PH, Thappa DM, et al. Platelet activation in chronic urticaria and its correlation with disease severity. Platelets. 2014;25:162–5.
Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393–414.
Shibamoto T, Liu W, Cui S, Zhang W, Takano H, Kurata Y. PAF, rather than histamine, participates in mouse anaphylactic hypotension. Pharmacology. 2008;82:114–20.
Vadas P, Gold M, Perelman B, Liss GM, Lack G, Blyth T, et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med. 2008;358:28–35.
Ye YM, Park JW, Kim SH, Ban GY, Kim JH, Shin YS, et al. Prognostic factors for chronic spontaneous urticaria: a 6-month prospective observational study. Allergy Asthma Immunol Res. 2016;8:115–23.
Konstantinou GN, Asero R, Maurer M, Sabroe RA, Schmid-Grendelmeier P, Grattan CE. EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy. 2009;64:1256–68.
Trinh HK, Pham DL, Ban GY, Lee HY, Park HS, Ye YM. Altered systemic adipokines in patients with chronic urticaria. Int Arch Allergy Immunol. 2016;171:102–10.
Vadas P, Perelman B, Liss G. Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. J Allergy Clin Immunol. 2013;131:144–9.
Palgan K, Bartuzi Z. Platelet activating factor in allergies. Int J Immunopathol Pharmacol. 2015;28:584–9.
Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci. 2003;40:643–72.
Stewart GE 2nd. Histopathology of chronic urticaria. Clin Rev Allergy Immunol. 2002;23:195–200.
Jenks PJ, Kavanagh GM, Brooks J, Bradfield JW, Archer CB. Comparison of weal and flare responses to platelet activating factor (PAF) and histamine, and the ultrastructural effects of PAF in the skin of atopic and normal subjects. Clin Exp Dermatol. 1999;24:112–7.
Amin P, Levin L, Holmes SJ, Picard J, Bernstein JA. Investigation of patient-specific characteristics associated with treatment outcomes for chronic urticaria. J Allergy Clin Immunol Pract. 2015;3:400–7.
Stafforini DM. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther. 2009;23:73–83.
Ye YM, Jin HJ, Hwang EK, Nam YH, Kim JH, Shin YS, et al. Co-existence of chronic urticaria and metabolic syndrome: clinical implications. Acta Derm Venereol. 2013;93:156–60.
Okada T, Miyashita M, Kuromori Y, Iwata F, Harada K, Hattori H. Platelet-activating factor acetylhydrolase concentration in children with abdominal obesity. Arterioscler Thromb Vasc Biol. 2006;26:e40–1.
Rizos E, Tambaki AP, Gazi I, Tselepis AD, Elisaf M. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids. 2005;72:203–9.
Tsukioka K, Matsuzaki M, Nakamata M, Kayahara H, Nakagawa T. Increased plasma level of platelet-activating factor (PAF) and decreased serum PAF acetylhydrolase (PAFAH) activity in adults with bronchial asthma. J Investig Allergol Clin Immunol. 1996;6:22–9.
Stafforini DM, Numao T, Tsodikov A, Vaitkus D, Fukuda T, Watanabe N, et al. Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. J Clin Invest. 1999;103:989–97.
Tedeschi A, Palumbo G, Milazzo N, Miadonna A. Nasal neutrophilia and eosinophilia induced by challenge with platelet activating factor. J Allergy Clin Immunol. 1994;93:526–33.
Munoz-Cano R, Valero A, Roca-Ferrer J, Bartra J, Sanchez-Lopez J, Mullol J, et al. Platelet-activating factor nasal challenge induces nasal congestion and reduces nasal volume in both healthy volunteers and allergic rhinitis patients. Am J Rhinol Allergy. 2013;27:e48–52.
Chung KF, Barnes PJ. Role for platelet-activating factor in asthma. Lipids. 1991;26:1277–9.
Kasperska-Zajac A, Brzoza Z, Rogala B. Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. Recent Pat Inflamm Allergy Drug Discov. 2008;2:72–6.
Ishii S, Kuwaki T, Nagase T, Maki K, Tashiro F, Sunaga S, et al. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J Exp Med. 1998;187:1779–88.
Finkelman FD, Rothenberg ME, Brandt EB, Morris SC, Strait RT. Molecular mechanisms of anaphylaxis: lessons from studies with murine models. J Allergy Clin Immunol. 2005;115:449–57 (quiz 58).
Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy. 2011;66:317–30.
Ni J, Ma X, Zhou M, Pan X, Tang J, Hao Y, et al. Serum lipocalin-2 levels positively correlate with coronary artery disease and metabolic syndrome. Cardiovasc Diabetol. 2013;12:176.
Deza G, Ricketti PA, Gimenez-Arnau AM, Casale TB. Emerging biomarkers and therapeutic pipelines for chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2018;6:1108–17.
Takahagi S, Mihara S, Iwamoto K, Morioke S, Okabe T, Kameyoshi Y, et al. Coagulation/fibrinolysis and inflammation markers are associated with disease activity in patients with chronic urticaria. Allergy. 2010;65:649–56.
Dubertret L, Zalupca L, Cristodoulo T, Benea V, Medina I, Fantin S, et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol. 2007;17:223–8.
Shamizadeh S, Brockow K, Ring J. Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects. Allergo J Int. 2014;23:87–95.
Arias K, Baig M, Colangelo M, Chu D, Walker T, Goncharova S, et al. Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. J Allergy Clin Immunol. 2009;124(307–14):14.e1–2.
Compalati E, Canonica GW. Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Curr Med Res Opin. 2013;29:1539–51.
Abajian M, Curto-Barredo L, Krause K, Santamaria E, Izquierdo I, Church MK, et al. Rupatadine 20 mg and 40 mg are effective in reducing the symptoms of chronic cold urticaria. Acta Derm Venereol. 2016;96:56–9.
The biospecimens from healthy normal controls for this study were provided by the Ajou University Human Bio-Resource Bank (AHBB), a member of the Korea Biobank Network, which is supported by the Ministry of Health and Welfare.
This work was supported by a grant from the National Research Foundation of Korea (NRF) funded by the Korea government (MSIP) (NRF-2018R1A2B6006199) and a research grant from Ahn-Gook Pharmaceutical Co, Ltd, Seoul, Republic of Korea (Grant No. 2018–2019).
Ethics approval and consent to participate
The study was approved by the Institutional Review Board of Ajou University Medical Center (AJIRB-BMR-SMP-18-74). Written informed consent was collected from all study subjects.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.